Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY5 | O95622 | 14/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.57 |
| ▸ | AHCY | P23526 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30969131 | 1.00 | ADCY5 (0.74) | ADCY5ADORA2BAHCYADORA2AADORA3 | |
| SCHEMBL5997273 | 1.00 | ADCY5 (0.74) | ADCY5ADORA2BAHCYADORA2AADORA3 | |
| SCHEMBL111590 | 1.00 | ADCY5 (0.74) | ADCY5ADORA2BAHCYADORA2AADORA3 | |
| SCHEMBL12157255 | 1.00 | ADCY5 (0.74) | ADCY5ADORA2BAHCYADORA2AADORA3 | |
| SCHEMBL5998483 | 1.00 | ADCY5 (0.74) | ADCY5ADORA2BAHCYADORA2AADORA3 | |
| Succinic Acid SCHEMBL7218517 | 0.93 | ADCY5 (0.79) | ADCY5ADORA2BAHCYADORA2AADORA3 | |
| SCHEMBL14046400 | 0.88 | ADCY5 (0.62) | ADCY5ADORA2BAHCYADORA2AADORA3 | |
| SCHEMBL14046406 | 0.88 | ADCY5 (0.62) | ADCY5ADORA2BAHCYADORA2AADORA3 | |
| SCHEMBL7248842 | 0.85 | ADCY5 (0.55) | ADCY5ADORA2BAHCYADORA2AADORA3 | |
| SCHEMBL6045726 | 0.85 | ADCY5 (1.00) | ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630477-B1 | Therapeutic nucleoside compound | SMITHKLINE BEECHAM CORPORATION | 2003-10-07 | — | — | US | claimed |
| EP-1150988-B1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LTD (GB) | 2003-05-28 | — | — | EP | claimed |
| EP-1150981-B1 | USE OF (1R, 4S)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL IN HBV | GLAXO GROUP LTD (GB) | 2003-04-16 | — | — | EP | claimed |
| WO-2016014527-A2 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-7115590-B1 | Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R, cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2006-10-03 | — | — | US | disclosed |
| US-7115590-B1 | Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R, cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2006-10-03 | — | — | US | disclosed |
| CN-1803810-A | Antiviral agents and preparing method thereof | GLAXO GROUP LTD (GB) | 2006-07-19 | — | — | CN | disclosed |
| US-6630477-B1 | Therapeutic nucleoside compound | SMITHKLINE BEECHAM CORPORATION | 2003-10-07 | — | — | US | disclosed |
| US-6630477-B1 | Therapeutic nucleoside compound | SMITHKLINE BEECHAM CORPORATION | 2003-10-07 | — | — | US | disclosed |
| EP-1150988-B1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LTD (GB) | 2003-05-28 | — | — | EP | disclosed |
| EP-1150988-B1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LTD (GB) | 2003-05-28 | — | — | EP | disclosed |
| CN-1346360-A | Phosphoramidates and di-and tri-phosphate esters of (1R, cis) -4- (6-amino-9H-purin-9-yl) -2-cyclopentene-1-methanol as antiviral agents | GLAXO GROUP LTD (GB) | 2002-04-24 | — | — | CN | disclosed |
| CN-1346356-A | Therapeutic nucleoside compound | GLAXO GROUP LTD (GB) | 2002-04-24 | — | — | CN | disclosed |
| EP-1150988-A1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2001-11-07 | — | — | EP | disclosed |
| EP-1150988-A1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047591-A1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000047591-A1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | NUDT1, DUT, ADAR | ADCY5 1177/4885ADORA2B 135/4885AHCY 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.